, Volume 70, Issue 3, pp 261–272

Rituximab for the Treatment of Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukaemia

Review Article


Rituximab is a monoclonal antibody that is widely utilized in the treatment of a number of B-cell-derived haematological malignancies. Rituximab, in combination with chemotherapy, has significantly improved survival outcomes for patients diagnosed with follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL), the two most commonly diagnosed subtypes of non-Hodgkin’s lymphoma. Furthermore, chemoimmunotherapy containing rituximab has led to significant increases in complete response and progression-free survival rates for patients with both previously untreated and relapsed or refractory chronic lymphocytic leukaemia (CLL). This article reviews the efficacy data from clinical trials demonstrating the significant survival benefits associated with rituximab use in the treatment of FL, DLBCL and CLL.


  1. 1.
    Olszewski AJ, Grossbard ML. Empowering targeted therapy: lessons from rituximab [letter]. Sci STKE 2004 Jul; 2004(241): pe30PubMedCrossRefGoogle Scholar
  2. 2.
    Garcia-Sanz R, Orfão A, González M, et al. Primary plasma cell leukemia: clinical, immunophenotypic, DNA ploidy, and cytogenetic characteristics. Blood 1999 Feb; 93(3): 1032–7PubMedGoogle Scholar
  3. 3.
    Srinivas S, Yook C, Chang V, et al. Prevalence of bone marrow CD20 positivity in patients (pts) with multiple myeloma (MM) [abstract no. 2687]. J Clin Oncol 2001; 20 (Suppl.)Google Scholar
  4. 4.
    Treon SP, Kelliher A, Keele B, et al. Expression of serotherapy target antigens in Waldenstrom’s macroglobulinemia: therapeutic applications and considerations. Semin Oncol 2003 Apr; 30(2): 248–52PubMedCrossRefGoogle Scholar
  5. 5.
    Glennie MJ, French RR, Cragg MS, et al. Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol Immunol 2007 Sep; 44(16): 3823–37PubMedCrossRefGoogle Scholar
  6. 6.
    Shan D, Ledbetter J, Press OW. Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood 1998 Mar; 91(5): 1644–52PubMedGoogle Scholar
  7. 7.
    Shan D, Ledbetter J, Press OW. Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells. Cancer Immunol Immunother 2000 Mar; 48(12): 673–83PubMedCrossRefGoogle Scholar
  8. 8.
    Hofmeister JK, Cooney D, Coggeshall KM. Clustered CD20 induced apoptosis: src family kinase, the proximal regulator of tyrosine phosphorylation, calcium influx, and caspase 3-dependent apoptosis. Blood Cells Mol Dis 2000 Apr; 26(2): 133–43PubMedCrossRefGoogle Scholar
  9. 9.
    Demidem A, Hanna N, Hariharan H, et al. Chimeric anti-CD20 antibody (IDEC C2B8) is apoptotic and sensitizes drug-resistant human B cell lymphomas to the cytotoxic effect of CDDP, VP-16 and toxins [abstract]. FASEB J 1996; 9 (Suppl.): A206Google Scholar
  10. 10.
    Alas S, Bonavida B. Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B-non-Hodgkin’s lymphoma through inhibition of the interleukin 10 autocrine/paracrine loop and results in down-regulation of Bcl-2 and sensitization to cytotoxic drugs. Cancer Res 2001 Jul; 61(13): 5137–44PubMedGoogle Scholar
  11. 11.
    Alas S, Emmanouilides C, Bonavida B, et al. Inhibition of IL-10 by Rituximab inactivates results in down-regulation of Bcl-2 and sensitization of B cell non-Hodgkin’s lymphoma to apoptosis. Clin Cancer Res 2001 Mar; 7(3): 709–23PubMedGoogle Scholar
  12. 12.
    Di Gaetano N, Xiao Y, Erba E, et al. Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone. Br J Haematol 2001 Sep; 114(4): 800–9PubMedCrossRefGoogle Scholar
  13. 13.
    Chow KU, Sommerlad WD, Boehrer S, et al. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases. Haematologica 2002 Jan; 87(1): 33–43PubMedGoogle Scholar
  14. 14.
    National Comprehensive Cancer Network. NCCN—drugs & biologics compendium [online]. Available from URL: http://www.nccn.org/professionals/drug_compendium/content/contents.asp [Accessed 2009 Feb 17]
  15. 15.
    National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology, non-Hodgkin’s lymphoma: V.I.2009 [online]. Available from URL: http://www.nccn.org/professionals/physician_gls/PDF/nhl.pdf[Accessed 2009 Feb 17]
  16. 16.
    Rituxan prescribing information [online]. Available from URL: http://www.gene.com/gene/products/information/pdf/rituxan-prescribing.pdf[Accessed 2009 Feb 17]
  17. 17.
    European Medicine Agency. European public assessment report for MabThera [online]. Available from URL: http://www.emea.europa.eu/humandocs/Humans/EPAR/mabthera/mabthera.htm [Accessed 2009 July 12]
  18. 18.
    Hornberger J, Reyes C, Lubeck D, et al. Economic evaluation of rituximab plus cyclophosphamide, vincristine and prednisolone for advanced follicular lymphoma. Leuk Lymph 2008 Feb; 49(2): 227–36CrossRefGoogle Scholar
  19. 19.
    Hornberger JC, Best JH. Cost utility in the United States of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone for the treatment of elderly patients with diffuse large B-cell lymphoma. Cancer 2005 Apr; 103(8): 1644-51Google Scholar
  20. 20.
    Hayslip JW, Simpson KN. Cost-effectiveness of extended adjuvant rituximab for US patients aged 65–70 years with follicular lymphoma in second remission. Clin Lymph Myel 2008 Jun; 8(3): 166–70CrossRefGoogle Scholar
  21. 21.
    Carr E, Lerner S, Rick Aultman R, et al. Treatment effect of first line rituximab, fludarabine and cyclophosphamide in a chronic lymphocytic leukemia patient cohort: an evaluation of prognostic factors, estimated life expectancy and economic outcomes [abstract no. 2396]. Blood (ASH Annual Meeting Abstracts) 2008; 112 (Suppl.)Google Scholar
  22. 22.
    American Cancer Society. Cancer facts and figures 2009 [online]. Available from URL: http://www.cancer.org/docroot/STT/content/STT_1x_Cancer_Facts_Figures_2009.asp?from=fast [Accessed 2009 Jul 12]
  23. 23.
    Armitage JO. The changing classification of non-Hodgkin’s lymphomas. CA Cancer J Clin 1997 Nov–Dec; 47(6): 323–5PubMedCrossRefGoogle Scholar
  24. 24.
    Cheson BD, Gregory SA, Marcus R. Emerging treatments for indolent lymphoma. Clin Adv Hematol Oncol 2007 May; 5 (5 Suppl.): 1–9PubMedGoogle Scholar
  25. 25.
    Schulz H, Bohlius JF, Trelle S, et al. Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst 2007 May; 99(9): 706–14PubMedCrossRefGoogle Scholar
  26. 26.
    Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005 Dec; 106(12): 3725–32PubMedCrossRefGoogle Scholar
  27. 27.
    Salles G, Mounier N, de Guibert S, et al. Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study. Blood 2008 Dec; 112(13): 4824–31PubMedCrossRefGoogle Scholar
  28. 28.
    Herold M, Haas A, Srock S, et al. Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. J Clin Oncol 2007 May; 25(15): 1986–92PubMedCrossRefGoogle Scholar
  29. 29.
    Marcus RE, Imrie K, Solal-Celigny P, et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol 2008 Oct; 26(28): 4579–86PubMedCrossRefGoogle Scholar
  30. 30.
    Forstpointner R, Dreyling M, Repp R, et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2004 Nov; 104(10): 3064–71PubMedCrossRefGoogle Scholar
  31. 31.
    van Oers MH, Klasa R, Marcus RE, et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin’s lymphoma, both in patients with and without rituximab during induction: results of a prospective randomized phase III intergroup trial. Blood 2006 Nov; 108(10): 3295–301PubMedCrossRefGoogle Scholar
  32. 32.
    Ghielmini ME, Hsu Schmitz S, Martinelli G, et al. Long-term follow-up of patients with follicular lymphoma (FL) receiving single agent rituximab at two different schedules in study SAKK 35/98 [abstract no. 8512]. J Clin Oncol 2009; 27 (15S Suppl.)Google Scholar
  33. 33.
    Hochster HS, Weller E, Gascoyne RD, et al. Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 study. J Clin Oncol 2009 Apr; 27(10): 1607–14PubMedCrossRefGoogle Scholar
  34. 34.
    Hainsworth JD, Litchy S, Shaffer DW, et al. Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non Hodgkin’s lymphoma: a randomized phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 2005 Feb; 23(6): 1088–95PubMedCrossRefGoogle Scholar
  35. 35.
    Forstpointner R, Unterhalt M, Dreyling M, et al. Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide and mitoxantrone (R-FCM) in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood 2006 Dec; 108(13) 4003–8PubMedCrossRefGoogle Scholar
  36. 36.
    Pfreundschuh M, Trumper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006 May; 7(5): 379–91PubMedCrossRefGoogle Scholar
  37. 37.
    Habermann TM, Weller EA, Morrison VA, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006 Jul; 24(19): 3121–37PubMedCrossRefGoogle Scholar
  38. 38.
    Coiffier B, Gisselbrecht C, Bosly A, et al. 10 years follow-up of the GELA LNH98.5 study, first randomized study comparing R-CHOP to CHOP chemotherapy in patients with diffuse large B-cell lymphoma [abstract no. 3741]. Blood (ASH Annual Meeting Abstracts) 2009; 114Google Scholar
  39. 39.
    van Oers MH. Rituximab maintenance therapy: a step forward in follicular lymphoma. Haematologica 2007 Jun; 92(6): 826–32PubMedCrossRefGoogle Scholar
  40. 40.
    Gisselbrecht C. Use of rituximab in diffuse large B-cell lymphoma in the salvage setting. Br J Haematology 2008 Dec; 143(5): 607–21CrossRefGoogle Scholar
  41. 41.
    Kewalramani T, Zelenetz AD, Nimer SD, et al. Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood 2004 May; 103(10): 3684–8PubMedCrossRefGoogle Scholar
  42. 42.
    Haioun C, Mounier N, Emile JF, et al. Rituximab compared to observation after high-dose consolidative first-line chemotherapy (HDC) with autologous stem cell transplantation in poor-risk diffuse large B-cell lymphoma: updated results of the LNH98-B3 GELA study [abstract no. 8012]. J Clin Oncol 2007; 25 (15S Suppl.)Google Scholar
  43. 43.
    Gisselbrecht C, Glass B, Mounier N, et al. R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by autologous stem cell transplantation: CORAL study [abstract no. 8509]. J Clin Oncol 2009; 27 (15S Suppl.)Google Scholar
  44. 44.
    Fayad L, Thomas D, Romaguera J. Update of the M. D. Anderson Cancer Center experience with hyper-CVAD and rituximab for the treatment of mantle cell and Burkitt-type lymphomas. Clin Lymph Myel 2007 Dec; 8 Suppl. 2: 57S-62SCrossRefGoogle Scholar
  45. 45.
    Robinson KS, Williams ME, van der Jagt RH, et al. Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin’s lymphoma. J Clin Oncol 2008 Sep; 26(27): 4473–9PubMedCrossRefGoogle Scholar
  46. 46.
    Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) updating the National Cancer Institute-Working Group (NCI-WG) 1996 guidelines. Blood 2008 Jun; 111(12): 5446–56PubMedCrossRefGoogle Scholar
  47. 47.
    Johnson S, Smith AG, Loffler H, et al. Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advancedstage chronic lymphocytic leukaemia. The French Cooperative Group on CLL. Lancet 1996 May; 347(9013): 1432–8PubMedGoogle Scholar
  48. 48.
    Leporrier M, Chevret S, Cazin B, et al. Randomized comparison of fludarabine, CAP, and CHOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients. Blood 2001 Oct; 98(8); 2319–25PubMedCrossRefGoogle Scholar
  49. 49.
    Byrd JC, Rai K, Peterson BL, et al. The addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood 2005 Jan; 105(1): 49–53PubMedCrossRefGoogle Scholar
  50. 50.
    Tam CS, O’Brien S, Wierda W, et al. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 2008 Aug; 112(4): 975–80PubMedCrossRefGoogle Scholar
  51. 51.
    Hallek M, Fingerle-Rowson G, Fink A-M, et al. First-line treatment with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) improves overall survival (OS) in previously untreated patients (pts) with advanced chronic lymphocytic leukemia (CLL): results of a randomized phase III trial on behalf of an international group of investigators and the German CLL Study Group [abstract no. 535]. Blood (ASH Annual Meeting Abstracts) 2009; 114Google Scholar
  52. 52.
    Wierda W, O’Brien S, Faderl S, et al. A retrospective comparison of three sequential groups of patients with recurrent/refractory chronic lymphocytic leukemia treated with fludarabine-based regimens. Cancer 2006 Jan; 106(2): 337–45PubMedCrossRefGoogle Scholar
  53. 53.
    Wierda W, O’Brien S, Wen S, et al. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol 2005 Jun; 23(18): 4070–8PubMedCrossRefGoogle Scholar
  54. 54.
    Robak T, Moiseev SI, Dmoszynska A, et al. Rituximab, fludarabine, and cyclophosphamide (R-FC) prolongs progression free survival in relapsed or refractory chronic lymphocytic leukemia (CLL) compared with FC alone: final results from the international randomized Phase III REACH trial [abstract no. LBA-1]. Blood (ASH Annual Meeting Abstracts) 2008; 112Google Scholar
  55. 55.
    Byrd JC, Peterson BL, Morrison VA, et al. Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood 2003 Jan; 101(1): 6–14PubMedCrossRefGoogle Scholar
  56. 56.
    Hainsworth JD, Litchy S, Barton JH, et al. Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 2003 May; 21(9): 1746–51PubMedCrossRefGoogle Scholar
  57. 57.
    Byrd JC, Murphy T, Howard RS, et al. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol 2001 Apr; 19(8): 2153–64PubMedGoogle Scholar
  58. 58.
    Schulz H, Klein SK, Rehwald U, et al. Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia. Blood 2002 Nov; 100(9): 3115–20PubMedCrossRefGoogle Scholar
  59. 59.
    Stilgenbauer S, Zenz T, Winkler D, et al. Genomic aberrations, VH mutation status and outcome after fludarabine and cyclophosphamide (FC) or FC plus rituximab (FCR) in the CLL8 trial [abstract no. 781]. Blood (ASH Annual Meeting Abstracts) 2008; 112Google Scholar
  60. 60.
    Winter MC, Hancock BW. Ten years of rituximab in NHL. Expert Opin Drug Saf 2009 Mar; 8(2): 223–35PubMedCrossRefGoogle Scholar
  61. 61.
    Lenz HJ. Management and preparedness for infusion and hypersensitivity reactions. Oncologist 2007 May; 12(5): 601–9PubMedCrossRefGoogle Scholar
  62. 62.
    Horning SJ. Follicular lymphoma, survival, and rituximab: is it time to declare victory? J Clin Oncol 2008 Oct; 26(28): 4537–8PubMedCrossRefGoogle Scholar
  63. 63.
    United States National Institutes of Health. Clinical Trials.gov. Rituximab clinical trials [online]. Available from URL: http://www.clinicaltrials.gov/ct2/results?term=rituximab [Accessed 2009 Jan 13]
  64. 64.
    Taverna CJ, Bassi S, Hitz F, et al. First results of long-term rituximab maintenance treatment in follicular lymphoma: safety analysis of the randomized phase III trial SAKK 35/03 [abstract no. 8534]. J Clin Oncol 2009; 27 (15S Suppl.)Google Scholar
  65. 65.
    Wenger MK, Foa R, Arcaini L, et al. Safety in patients receiving maintenance rituximab for follicular lymphoma: results from the phase IIIb MAXIMA trial [abstract no. 8606]. J Clin Oncol 2008; 26 (15S Suppl.)Google Scholar
  66. 66.
    Friedberg JW, Taylor MD, Cerhan JR, et al. Follicular lymphoma in the United States: first report of the National LymphoCare Study. J Clin Oncol 2009 Mar; 27(8): 1202–8PubMedCrossRefGoogle Scholar
  67. 67.
    Rummel MJ, von Gruenhagen U, Niederle N, et al. Bendamustine plus rituximab versus CHOP plus rituximab in the first-line-treatment of patients with follicular, indolent and mantle cell lymphomas: results of a randomized phase III study of the Study Group indolent Lymphomas (StiL) [abstract no. 2596]. Blood (ASH Annual Meeting Abstracts) 2008; 112Google Scholar
  68. 68.
    Fischer K, Stilgenbauer S, Schweighofer CD, et al. Bendamustine in combination with rituximab (BR) for patients with relapsed chronic lymphocytic leukemia (CLL): a multicentre phase II trial of the German CLL Study Group (GCLLSG) [abstract no. 330]. Blood (ASH Annual Meeting Abstracts) 2008; 112Google Scholar

Copyright information

© Adis Data Information BV 2010

Authors and Affiliations

  1. 1.Department of Lymphoma and MyelomaThe University of Texas M.D. Anderson Cancer CenterHoustonUSA

Personalised recommendations